Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 157 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Rapamune and Prograf Clear all

Conditions: Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Etoposide, Fractionated Stereotactic Radiation Therapy, Goat Milk, Palifermin, Sirolimus, Tacrolimus; Procedure · Drug · Radiation + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 12 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Graft Versus Host Disease, Hematologic Malignancies
Interventions: Sirolimus, Tacrolimus, Methotrexate, Stem Cell Transplantation; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Graft Failure, Sickle Cell Disease, Hemoglobinopathies
Interventions: Alemtuzumab, Total Body Irradiation, Cell Infusion, Thymoglobulin, Fludarabine, Busulfan, Cyclophosphamide, Sirolimus, Tacrolimus, Mycophenolate Mofetil, Plerixafor (mozobil); Drug · Radiation · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 55 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Absence; Kidney
Interventions: rapamune, mycophenolate mofetil and steroid, tacrolimus, sirolimus and steroid; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: End Stage Renal Disease
Interventions: Tacrolimus, Everolimus; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression
Interventions: Alemtuzumab, Tacrolimus, Mycophenolate mofetil, Sirolimus; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Year to 20 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 4
States / cities: San Francisco, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more

Conditions: Liver Transplantation
Interventions: Tacrolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Everolimus (reduced tacrolimus), Everolimus (tacrolimus elimination), Corticosteroids; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 28
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 20 more

Conditions: Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Leukemia, Multiple Myeloma
Interventions: Rituximab, Conditioning chemotherapy, TMS, FLAG, EPOCH-F, Hematopoietic stem cell transplant, Palifermin, Acetaminophen, Diphenhydramine, Prednisone, Epinephrine, IV Saline, ECG, ECHO, MUGA, DEXA, CT chest, PET, MRI, BM aspirate, BM biopsy, Lumbar puncture; Biological · Drug · Procedure + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Conditions: Liver Transplantation
Interventions: Anti-Thymocyte Globulin - Rabbit, darTreg Infusion, Everolimus, Tacrolimus, Mycophenolate mofetil, Prednisone, Acetaminophen, Diphenhydramine, Anti-Infective Prophylaxis, Leukapheresis, Blood draws, Liver biopsies, Liver transplantation; Biological · Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 21 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Rochester, Minnesota

Conditions: Kidney Transplantation
Interventions: Kidney Biopsy, Rapamune (sirolimus/rapamycin), Tacrolimus; Procedure · Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Adult Primary Kidney Transplantation
Interventions: Tacrolimus/Sirolimus, Tacrolimus/MMF, Neoral/Sirolimus; Drug
Lead sponsor: University of Miami; Other
Eligibility: 16 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Chronic Graft-versus-host-disease
Interventions: INCA034176, Best available Treatment (BAT); Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 9 more

Conditions: Graft vs. Host Disease
Interventions: Ustekinumab, Placebo, Tacrolimus (TAC), Sirolimus; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Multiple Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Myelogenous Leukemia, Lymphoblastic Leukemia
Interventions: Tacrolimus, Sirolimus, G-CSF, Antithymocyte globulin, Thymoglobulin, Fludarabine, Melphalan; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Leukemia, Non-Hodgkins Lymphoma, Hodgkins Lymphoma, MDS, Multiple Myeloma
Interventions: EPOCH-F/R, FLAG, Transplant Preparative Regimen (Flu/Cy/Mes), GVHD Prophylaxis (tacrolimus and sirolimus), Double Cord Blood Transplantation; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 69 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Immunosuppression, Renal Failure
Interventions: Arm A: Everolimus, Calcineurin Inhibitor; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Polycystic Liver Disease
Interventions: Tacrolimus, Sirolimus, Mycophenolate Mofetil, Prednisone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: End-Stage Renal Disease, Kidney Transplantation
Interventions: Cyclosporine, Sirolimus, Tacrolimus; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 20 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes, Hypoglycemia
Interventions: Allogeneic islets of Langerhans transplant; Biological
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Systemic Sclerosis
Interventions: RIC alloBMT w PTCy in refractory SSc; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: bortezomib, fludarabine phosphate, melphalan, total marrow irradiation, tacrolimus, sirolimus, peripheral blood stem cell transplantation, laboratory biomarker analysis; Drug · Other · Radiation + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Duarte, California

Conditions: Kidney Diseases
Interventions: Sirolimus; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Graft Rejection, Kidney Transplant, Renal Allograft Recipients, Renal Transplant
Interventions: Tacrolimus, Sirolimus; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 25
States / cities: La Jolla, California • San Francisco, California • Aurora, Colorado + 19 more

Conditions: Liver Transplantation
Interventions: mycophenolate mofetil [CellCept], Tacrolimus, Cyclosporine, Sirolimus; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 31 more

Search by objective public record fields.

Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation

Allo HSCT for High Risk Hemoglobinopathies

Sirolimus Conversions in African-American Renal Transplant Recipients

Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus

Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation

Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal

Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney Transplantation

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease

Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus

Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders

Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.

Polycystic Liver Disease in Kidney Transplant

A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant

Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes

RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Comparison of Sirolimus to Tacrolimus for Long Term Therapy in Kidney Transplant With no Steroids

Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients

Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant